Ascendis Pharma A (ASND) Receivables (2012 - 2026)
Ascendis Pharma A (ASND) posted Receivables of $209.2 million for Q1 2026, up 15.26% sequentially from $181.5 million in Q4 2025, and up 164.42% YoY from $79.1 million in Q1 2025.
Ascendis Pharma A (ASND) Receivables (2012 - 2026) Analysis & Trends
Ascendis Pharma A has reported Receivables for 15 years, with the latest figure at $209.2 million in Q1 2026.
- Quarterly Receivables rose 164.42% year-over-year to $209.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $209.2 million (up 164.42% YoY) and the FY2025 annual result came in at $181.5 million, down 3.32% from the prior year.
- Receivables grew to $209.2 million in Q1 2026 per ASND's latest filing, from $181.5 million in the prior quarter.
- Over five years, Receivables peaked at $209.2 million in Q1 2026 and troughed at $20.1 million in Q3 2022.
- A 5-year average of $85.1 million and a median of $59.1 million in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2025: Receivables decreased 18.09% in 2022, then surged 217.68% in 2025.
- Over 5 years, Receivables stood at $25.2 million in 2022, then jumped by 134.3% to $59.1 million in 2023, then surged by 217.38% to $187.7 million in 2024, then decreased by 3.32% to $181.5 million in 2025, then advanced by 15.26% to $209.2 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $209.2 million, $181.5 million, and $168.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 209.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209.18 Mn |
| Dec 31, 2025 | 181.49 Mn |
| Sep 30, 2025 | 168.71 Mn |
| Jun 30, 2025 | 134.12 Mn |
| Mar 31, 2025 | 79.11 Mn |
| Dec 31, 2024 | 187.71 Mn |
| Sep 30, 2024 | 53.11 Mn |
| Jun 30, 2024 | 84.90 Mn |
| Mar 31, 2024 | 73.82 Mn |
| Dec 31, 2023 | 59.15 Mn |
| Sep 30, 2023 | 52.68 Mn |
| Jun 30, 2023 | 37.39 Mn |
| Mar 31, 2023 | 35.95 Mn |
| Dec 31, 2022 | 25.24 Mn |
| Sep 30, 2022 | 20.08 Mn |
| Jun 30, 2022 | 20.73 Mn |
| Mar 31, 2022 | 23.43 Mn |
| Dec 31, 2021 | 25.50 Mn |
| Sep 30, 2021 | 24.52 Mn |
| Jun 30, 2021 | 14.20 Mn |